Subject(s)
Aftercare , COVID-19/physiopathology , Hospitalization , Lung/physiopathology , Aged , Asthma/epidemiology , COVID-19/diagnostic imaging , COVID-19/epidemiology , COVID-19/therapy , Comorbidity , Critical Illness , Dyspnea/physiopathology , Female , Humans , Lung/diagnostic imaging , Male , Middle Aged , Pulmonary Diffusing Capacity , Pulmonary Disease, Chronic Obstructive/epidemiology , Respiratory Function Tests , SARS-CoV-2 , Severity of Illness Index , Tomography, X-Ray Computed , Total Lung Capacity , Walk TestABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic has spread rapidly worldwide, with more than two million deaths. Evidence indicates the critical role of the vascular endothelium in its pathophysiology but, like potential changes in functional vasodilation, the vascular effect of SARS-CoV-2 at a given distance from the acute infection is largely unknown. We assessed brachial artery flow-mediated dilatation (FMD) in 27 COVID-19 patients needing conventional or intensive care unit hospitalization, three months after SARS-CoV-2 infection diagnosis and in nine age- and sex- matched control subjects. Interestingly, the FMD was lower in COVID-19 patients as compared to controls (8.2 (7.2-8.9) vs. 10.3 (9.1-11.7)); p = 0.002, and half of the hospitalized COVID-19 survivors presented with a reduced FMD < 8% at three months of COVID-19 onset. Impaired FMD was not associated with severe or critical SARS-CoV-2 infection, reflected by ICU hospitalization, total hospitalization duration, or severity of lung damage. In conclusion, reduced FMD is often observed even three months after hospitalization for SARS-CoV-2 infection, but such alteration predominantly appears to not be related to COVID-19 severity. Longer and larger follow-up studies will help to clarify the potential prognosis value of FMD among COVID-19 patients, as well as to further determine the mechanisms involved.